Clinical Trial Update: A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial evaluating immunization with lymphotactin and interleukin-2 gene-modified neuroblastoma tumor cells; study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Lymphotactin and Interleukin-2 gene-modified neuroblastoma tumor cells

Snippet

Sponsor: Baylor College of Medicine | Conditions: Neuroblastoma | Phase 1, Phase 2 | Status: COMPLETED